Trial · NCT02072824
Results by group330
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 330
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | 1.69 | Standard Error 0.115 | seizures per 24 hours | |
| Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | 1.15 | Standard Error 0.163 | seizures per 24 hours | |
| Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase | Placebo | 1.58 | Standard Error 0.129 | seizures per 24 hours | |
Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | 30.51 | percentage of participants | ||
Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | 53.57 | percentage of participants | ||
Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase | Placebo | 41.51 | percentage of participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | AEs | 32 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | AEs | 17 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | AEs | 38 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | SAEs | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | SAEs | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | SAEs | 4 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | AEs | 15 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | AEs | 8 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | AEs | 13 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | SAEs | 0 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | SAEs | 0 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | SAEs | 1 | Participants | |
| Number of Adverse Events by Severity | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Mild | 60 | events | |
| Number of Adverse Events by Severity | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Mild | 23 | events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02072824/results